Crossmark

Fibrillarin and fibrillarin-like their role in cancer progression: new approaches and perspectives

Published Online: 2026-01-12

Published Print: 2026-12

Authors

Ceja-Lopez, Jaime Abelardo

Valdes, Jany

Miladinović, Ana

Antiga, Ludovica

Rodríguez-Zapata, Luis Carlos

Hozak, Pavel

Castaño, Enrique
Funding

Funding for this research was provided by:

Secretaría de Ciencia, Humanidades, Tecnología e Innovación (4016906)

Secretaría de Ciencia, Humanidades, Tecnología e Innovación (4024727)

Ústav Molekulární Genetiky, Akademie Věd České Republiky (68378050)

MEYS CR (LM2023050)

Grantová Agentura České Republiky (17-09103S)

Pan European Network in Lipidomics and EpiLipidomics (CA19105 EpiLipidNET)
License Information

Text and Data Mining valid from 2026-01-12

Version of Record valid from 2026-01-12
More Information

Article History

Received: 28 October 2025

Accepted: 6 January 2026

First Online: 12 January 2026

Declarations

:

: The authors declare no competing interests.

: This article does not contain any studies with any animals or human.

Document is current